KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBITDA Margin (2016 - 2025)

Charles River Laboratories International has reported EBITDA Margin over the past 17 years, most recently at 28.51% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1178.0% year-over-year to 28.51%; the TTM value through Dec 2025 reached 0.63%, down 499.0%, while the annual FY2025 figure was 0.63%, 499.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 28.51% at Charles River Laboratories International, down from 13.32% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 19.26% in Q2 2022 and troughed at 28.51% in Q4 2025.
  • A 5-year average of 10.81% and a median of 14.84% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 422bps in 2022 and later crashed -2984bps in 2024.
  • Year by year, EBITDA Margin stood at 19.09% in 2021, then fell by -22bps to 14.89% in 2022, then decreased by -12bps to 13.12% in 2023, then plummeted by -228bps to 16.73% in 2024, then crashed by -70bps to 28.51% in 2025.
  • Business Quant data shows EBITDA Margin for CRL at 28.51% in Q4 2025, 13.32% in Q3 2025, and 9.7% in Q2 2025.